MSB 8.76% 88.5¢ mesoblast limited

On 2nd of October 2020... “We’re going to have a meeting with...

  1. 12,448 Posts.
    lightbulb Created with Sketch. 3374
    On 2nd of October 2020...

    “We’re going to have a meeting with the FDA in the next 30 days to discuss an accelerated approval, which is a conditional pathway, and we will agree to do another trial but after the product gets approved,” Mesoblast CEO Silviu Itescu told BioWorld.

    So has the Type A Meeting request been submitted?


    Also, a bit of loose reporting...

    “The body of evidence around the use remestemcel-L in inflammatory conditions continues to build,” Itescu said. The stem cell therapy currently has emergency use authorization in the U.S. and Australia to treat ARDS due to COVID-19.

    EUA has not been given!!!
    We are still I'm a trial phase
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
88.5¢
Change
-0.085(8.76%)
Mkt cap ! $1.010B
Open High Low Value Volume
95.0¢ 95.0¢ 88.0¢ $9.657M 10.58M

Buyers (Bids)

No. Vol. Price($)
16 140818 88.0¢
 

Sellers (Offers)

Price($) Vol. No.
89.0¢ 3680 1
View Market Depth
Last trade - 16.10pm 05/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.